Pressure BioSciences Inc. (PBIO) Enters Contract Services Agreement with World-Renowned Biotherapeutics Firm
PBIO expects to achieve a significant revenue increase in 2019 and beyond through the expansion of its proprietary BaroFold platform into the estimated $44 billion global bioprocess technology market Over 200 therapeutic proteins and peptides are currently approved by the FDA for use with conditions such as cancer, immunological and metabolic disorders and infectious diseases Hundreds of additional protein and peptide-based drugs are in development worldwide PBIO’s proprietary BaroFold platform offers a unique and cost-effective way to address two of the most complex and challenging issues critical to the development and manufacture of therapeutic proteins Pressure BioSciences Inc. (OTCQB: PBIO),…